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Abstract
This review discusses recent progress in the development of anti-HIV agents targeting the viral
entry process. The three main classes (attachment inhibitors, co-receptor binding inhibitors, and
fusion inhibitors) are further broken down by specific mechanism of action and structure. Many of
these inhibitors are in advanced clinical trials, including the HIV maturation inhibitor bevirimat,
from the authors’ laboratories. In addition, the CCR5 inhibitor maraviroc has recently been FDA-
approved. Possible roles for these agents in anti-HIV therapy, including treatment of virus
resistant to current drugs, are also discussed.
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1. INTRODUCTION
An estimated 33.2 million people are infected worldwide with human immunodeficiency
virus (HIV), the etiologic cause of acquired immunodeficiency syndrome (AIDS). In 2007,
2.5 million people were newly infected with the virus, and 2.1 million people died of AIDS-
related illnesses,1 making this pandemic the fourth leading cause of mortality globally. The
successful development of a safe and effective HIV vaccine is still in the future.2 Therefore,
research continues to focus on disease treatment by chemical anti-HIV agents.
Significant progress has been made in the development of antiretroviral therapy (ART).
ART can successfully delay destruction of the immune system, reduce severity and
frequency of opportunistic infections, and consequently delay AIDS progression.
Introduction of highly active antiretroviral therapy (HAART), which employs a combination
of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs), can reduce viral load to
below detectable levels in patient plasma, resulting in improved patient health and life
span.3–6 However, the virus is suppressed rather than eradicated by HAART.7–9 On HAART
regimens, multiple drug therapies can lead to increased adverse effects and toxicities due to
long-term use and drug–drug interactions.10,11 Moreover, inadequate clinical viral
suppression of HIV-1 due to various reasons and the high error rate of the reverse
transcriptase lead to the emergence of drug-resistant and multi-drug-resistant viral strains.12
Drug-resistant virus is then involved in HIV transmission, and more than 25% of newly
infected individuals harbor HIV-1 isolates that are resistant to at least one ART.13,14
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Therefore, novel potent antiretroviral agents, which have simplified treatment regimens
(fewer pills and less-frequent administration), and target not only reverse transcriptase and
protease but also other viral targets, may hold particular promise in addressing issues of
current therapies.
Besides the viral enzyme reverse transcriptase (RT) and protease (PR), the life cycle of HIV
presents several potential targets for chemotherapeutic attack, including the viral entry
pathway, nuclear import of the pre-integration complex, integration, viral transcription,
processing of viral transcripts and nuclear export, and maturation.15,16 Among these targets,
viral entry is one of the most promising for HIV drug development. Indeed, enfuvirtide
(T-20, Fuzeon, Trimeris), which is a HIV fusion inhibitor, was the first drug with a target
other than RT and PR to be approved by the US FDA.17 Because the peptidic nature of
enfuvirtide does not permit its oral administration, the drug is currently administrated by
subcutaneous injection twice daily, which limits its application. Therefore, continued effort
in discovering new HIV entry inhibitors, especially potent, orally bioavailable small
molecules, is still needed. Herein, we review the development of new HIV entry inhibitors,
their mechanisms of action, and their possible role in anti-HIV therapy.
2. VIRAL ENTRY INHIBITORS
HIV entry into host cells is a complicated process that involves at least three steps: (1) an
attachment step that requires CD4 receptor binding, (2) co-receptor binding, and (3) fusion
process. The envelope glycoprotein (Env) on the surface of virions mediates entry.
Heterotrimeric Env spikes are composed of three surface glycoproteins (SU, gp120) atop
three transmembrane glycoproteins (TM, gp41).18 The gp41 subunits, which assemble into a
trimer, comprise the “stalk” of Env that anchors the Env into the viral membrane. The gp120
subunits comprise the “head” of Env that is able to bind to cellular receptors.19,20 Virions
can first attach to target cells in a relatively nonspecific manner, followed by specific
binding of HIV gp120 to the CD4 receptor on the cellular membrane. This binding induces a
conformational change in gp120 that opens up a high-affinity binding site located within the
third variable loop (V3) and surrounding surfaces for the chemokine co-receptors (primarily
CCR5 and CXCR4).21 Co-receptor binding results in further conformational rearrangements
of gp120 that expose the fusion-peptide domain of gp41. Insertion of this hydrophobic
domain into the cell membrane leads to the formation of a hairpin-like fold in the gp41
subunits.22 The heptad repeat (HR) regions, HR1 and HR2 of the three subunits of gp41,
fold and pack into a six-helix bundle, which brings the viral and cell membranes into
juxtaposition and creates pores in the target cell membrane, enabling the release of viral
capsid into the cytoplasm.23–26 Different entry inhibitors that target one or more of these
steps are now in preclinical and clinical trials.
A. Attachment Inhibitors
1. Nonspecific Attachment Inhibitors—Before gp120 and CD4 receptor binding
firmly attaches HIV onto the target cells, less specific adsorption and attachment occur
between the virions and cell membrane due to the interaction of the positively charged
regions of Env with oppositely charged proteoglycans of the cell surface.27,28 Studies have
reported that soluble polyanions, such as dextran sulfate, cyclodextrin sulfate and heparin,
can block this nonspecific attachment of HIV virions.29
Cyanovirin-N (Cellegy Pharmaceuticals*), an 11 kDa protein isolated from the
cyanobacterium (blue-green algae) Nostoc ellipsosporum, specifically binds to a conserved
*See Appendix for location of pharmaceutical companies.
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high-mannose carbohydrate region on gp120, which prevents the attachment of virus to
target cells at low nanomolar concentrations.30–32 Another example is PRO 2000 (Indevus
Pharmaceuticals), a naphthalene sulfonate polymer (1) (Fig. 1), which binds nonspecifically
to CD4 receptor.33 Vaginal PRO 2000 gel has been effective and well tolerated in Phase I/II
clinical trials.34,35 However, because of their mechanism of action and polymer properties,
these two compounds are mainly being developed as topical microbicides.
Glycyrrhizin (2) (Fig. 1), a triterpenoid saponin isolated from licorice root inhibits HIV-1
replication by partially blocking viral adsorption to CD4+ cells.36 Sulfation of glycyrrhizin
(3), amphotericin B, and lentinan, as well as polysulfonates [e.g., suramin (4)] and
polyhydroxycarboxylates [e.g., aurintricarboxylic acid (5)] also interfere with the
nonspecific viral attachment process (Fig. 1).
2. CD4-gp120 Binding Inhibitors—Many molecules can inhibit CD4 and gp120 binding
via different modes of action, including inhibition of attachment by targeting Env gp120 or
CD4 receptor and prevention of necessary conformational rearrangement.
PRO 542 (Progenics Pharmaceuticals) is a recombinant tetrameric CD4-IgG2 antibody-like
fusion protein, where the heavy and light chain Fv portions of human IgG2 have been
replaced by the D1 and D2 domains of human CD4.37 It targets the CD4 binding site on
gp120 by mimicking the CD4 receptor. In Phase I clinical trials, PRO 542 reduced viral load
after a single intravenous dose and was well tolerated in infected adults and children.38,39
TNX 355 (Tanox, Inc.) is a humanized IgG4 monoclonal antibody against CD4, which binds
to the D2 domain of CD4 and inhibits CD4-induced post-binding conformational changes.40
Phase I clinical studies concluded that TNX 355 reduced plasma HIV-1 RNA loads and
increased CD4+ T-cells.41 However, the need for infusion limits its clinical use.
BMS-378806 (6) and BMS-488043 (7) (Bristol-Myers Squibb) (Fig. 2) are novel, small-
molecule CD4-attachment inhibitors that specifically block HIV-1 entry by targeting Env
gp120 with an IC50 value of around 5 nM.42,43 Mechanism of action study revealed that
both compounds selectively bind to gp120 and lead to conformational changes in gp120 at
both the CD4 and CCR5 binding regions, which blocks CD4-gp120 interactions. Prior
addition of soluble CD4 to the assay system before BMS-488043 treatment negates the
inhibition activity of the compound, indicating that inhibition of CD4-gp120 binding is the
primary mode of action.44 An earlier report by Si et al.45 suggested that BMS analogs
function by blocking conformational changes of gp120 after CD4 binding rather than by
directly inhibiting CD4 binding; however, a significantly altered Env structure and high
concentrations of soluble CD4 may have led to this conclusion.44 Drug development of
BMS-378806 was discontinued after Phase I clinical study, because target exposure was not
achieved. BMS-488043 is currently in Phase II clinical trials.46 It is orally bioavailable with
superior pharmacokinetic properties and good safety profiles.
The New York Blood Center identified similar structures, NBD-556 (8) and NBD-557 (9)
(Fig. 2), which also contain an oxalamide moiety. These two compounds showed
micromolar potency against HIV-1.47 Compounds 10 and 11 (Fig. 2) disclosed by Pfizer,
Inc. in patents (WO-2005016344 and WO-2005121094) also share similar structures with
BMS analogs and have nanomolar anti-HIV activity.46
Zintevir (AR177, Aronex Pharmaceuticals), a 17-base G-quartet phosphorothioate
nucleotide, was first reported as a HIV integrase inhibitor.48 However, later research
discovered that it functions by blocking CD4-gp120 binding at sub-micromolar
concentration.49 However, an acute toxicity study in mice showed that AR177 caused male-
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specific mortality, and changes in serum chemistry, hematology, and histology at doses of
250 and 600 mg/kg, with renal necrosis and histologic vacuolization being prominent in
several organs.50 In comparison, AR177 did not cause significant hemodynamic toxicity in
cynomolgus monkeys, although lower doses of 20 and 50 mg/kg were administered.51
Overall, the toxicity of AR177 is considered species specific. Unfortunately, zintevir was
discontinued in Phase II clinical trials with no further indicated reasons.52
3. Down-Regulation of CD4 Expression—CADA analogs (cyclotriazadisulfonamide)
(12) (Fig. 2) have been identified as potent anti-HIV compounds with novel mechanism of
action.53 Binding studies with HIV-1 revealed that CADA did not directly interact with the
CD4 receptor and/or viral envelope glycoproteins. Further investigation discovered that
CADA analogs function by a specific CD4 down-modulating potency.54 Analysis of CD4
mRNA levels suggested that CADA regulation is not involved at the transcriptional level but
most probably interacts at a (post)translational level.55 Vermeire et al. further demonstrated
that the antiviral potency of the CADA analogs depended primarily on the down-regulation
of CD4 receptor expression. Removal of CADA compounds from the cell culture medium
resulted in complete restoration of CD4 expression. This category of compounds showed
anti-HIV entry activity at micromolar or sub-micromolar concentrations.56,57 Most recently,
this same group reported that they have successfully integrated a dansyl fluorophore into the
chemical structure of some CADA compounds, and showed the feasibility of tracking a
receptor and its down-modulator simultaneously.58 These fluorescent CADA analogs can
now be applied in further exploration on receptor modulation.
B. Co-Receptor Binding Inhibitors
Chemokine receptors belong to the seven transmembrane G protein coupled receptor family.
They are involved in the progression of many diseases, including rheumatoid arthritis,
transplant rejection, asthma, cancer, HIV, and others. CCR5 and CXCR4 are the main
chemokine receptors involved in the HIV entry process.59 Based on their chemokine
receptor usage, HIV isolates may be divided into R5, X4, and R5/X4 strains.60 R5 isolates
are the predominant virus strains, which are preferentially transmitted between HIV-infected
patients.61 However, R5 variants will eventually evolve into X4 isolates or R5/X4 isolates in
approximately 50% of HIV-1 positive individuals, resulting in increased viral replication
rate, faster disease progression, and the onset of AIDS.62
During the HIV entry process, the CD4-gp120 complex must further bind to chemokine co-
receptors in order to enter the target cells.63 The third variable region, V3, of gp120 is the
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major region implicated in co-receptor interactions. It is an approximately 35-residue-long,
frequently glycosylated, highly variable, disulfide-bonded structure that has a major
influence on HIV-1 tropism.64 The amino-acid sequences of V-3 can determine the usage of
CCR5 or CXCR4.65 Besides V3, a relatively well-conserved structure located partly on the
bridging sheet is also important for binding to both CCR5 and CXCR4 co-receptors.64
Epidemiology data shows that individuals homozygous for δ32 CCR5 allele (no expression
of CCR5 on cell surface) are highly resistant to HIV infection66,67 and apparently healthy.
This fact highlights the merits of targeting co-receptor binding to inhibit HIV entry.
1. CCR5 Inhibitors—The CCR5 co-receptor binding site on HIV gp120 is concealed by
V1, V2, and V3. The conformational change caused by the binding of gp120 with CD4
exposes this CCR5 binding site. When a CCR5 inhibitor is present, binding of the CCR5 N-
terminus and ECL2 (second extracellular loop) with the V3 stem of gp120 is blocked,
resulting in inhibition of viral entry.56 The strategies to block CCR5 co-receptor binding
include modified non-agonistic CCR5 chemokine natural ligands, CCR5 antibodies and
CCR5 small molecule antagonists.
RANTES (13) was discovered as the natural β-chemokines ligand, which can compete with
gp120 to bind the CCR5 co-receptor,68 and thus, inhibit HIV infection. However, it also
triggers CCR5-mediated down-stream signaling pathways, which may lead to undesired side
effects. Modification of RANTES at the N-terminus led to the discovery of AOP-RANTES
and NNY-RANTES, which are nanomolar level inhibitors of HIV R5 variants.69 C1,C5-
RANTES has two Ser to Cys substitutions at positions 1 and 5 of the wild type. It was the
first RANTES derivative without agonistic functions while maintaining high potency
towards HIV.70 Currently, PSC-RANTES (14) is under development as a potential
microbicide71 (Fig. 3).
PRO 140 (Progenics Pharmaceuticals) is another promising large molecule CCR5 co-
receptor binding inhibitor. It is a murine anti-CCR5 monoclonal antibody that binds a
complex epitope spanning multiple extracellular domains on CCR5.72 It does not prevent
CC-chemokine signaling, but still blocks the interactions of gp120 to CCR5. PRO 140
demonstrates a potent and genetic-subtype-independent anti-HIV-1 activity and is currently
in Phase II clinical trials.
Because large molecules are often difficult to administer, their clinical application may be
limited. Therefore, the search for orally bioavailable small molecule inhibitors remains of
great interest. This search has led to the discovery of many small molecule CCR5
antagonists, which are very promising for development as therapeutic antiviral drugs. These
small molecule CCR5 antagonists share a common binding site formed by the
transmembrane (TM) domains of CCR5. Although all antagonists sit in the same big
hydrophobic pocket, they occupy different subcavities. The residues involved in ligand
interaction are quite different for each of the antagonists.73 The putative binding pocket was
defined by Kondru et al.,73 and the key residues that line the binding pocket are identified as
Trp86, Tyr108, Phe109, Thr195, Ile198, Trp248, Tyr251, Glu283 (interacts with all
antagonists), and Met287.
TAK-799 (Takeda Chemical Industries) (15) (Fig. 4) is the first reported nonpeptide small
molecule that antagonizes the binding of RANTES to CCR5-expressing Chinese hamster
ovary cells at nanomolar concentrations (1.6–3.7 nM).74 TAK-799 selectively inhibits
CCR5 within the chemokine receptor family by binding inside a cavity formed by the
transmembrane helices 1, 2, 3, and 7 of the CCR5 receptor.75 Although it showed no
cytotoxicity to the host cells, lack of oral bioavailability limits its further development.
Clinical trials of an injectable quaternary ammonium salt TAK-799 were discontinued due
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to local reactions at injection sites. Modification of TAK-799 by replacing the quaternary
ammonium moiety with a polar sulfoxide moiety led to the discovery of TAK-652 (16)76
(Fig. 4). TAK-652 showed increased anti-HIV-1 activity against different clinical HIV
subtypes with a mean IC50 value of 0.25 nM. More importantly, it has oral bioavailability
and is well absorbed after oral administration in different preclinical animal studies.
TAK-652 is currently in Phase I/II clinical trials. Additional high throughput screening
against CCR5 in the same company led to the discovery of a different compound skeleton
exemplified by 17 (Fig. 4), which exhibits nanomolar anti-HIV-1 activity. However, 17 was
rapidly degraded in metabolic stability studies. Continuing modification resulted in the
identification of TAK-220 (18)77 (Fig. 4), an orally bioavailable, metabolically stable
piperidine-4-carboxamide derivative, which is also in clinical studies.
Maraviroc (MVC, UK-427,857, Pfizer, Inc.) (19) (Fig. 5) is another selective CCR5
antagonist with potent antiviral activity against all CCR5-tropic HIV-1 viruses at low
nanomolar concentrations (mean 90% inhibitory concentration of 2.0 nM).78 It was obtained
by medicinal chemistry optimization of a high throughput screening lead, the
imidazopyridine derivative UK-107,543 (20) (Fig. 5).78 The initial modification of 20 by
introducing an amide bond into the structure (21) (Fig. 5) solved the high lipophilicity
problem of the lead.79 Later study revealed that only the S enantiomer of 21 showed good
potency. However, this type of piperidine-based CCR5 antagonist is also a potent CYP 2D6
inhibitor, which may create problems with drug–drug interactions in drug combinational
use. Further development led to the discovery of tropane-based compound 22 (Fig. 5), which
does not inhibit CYP 2D6 liabilities, but retains high potency towards CCR5.80
Unfortunately, 22 is also a potent inhibitor of the hERG ion channel. This undesired side
effect was successfully conquered by replacing the benzimidazole group with a triazole
moiety and replacing the cyclobutyl group with a difluorocyclohexane moiety, which
resulted in the identification of maraviroc (19).81 Mechanism of action study revealed that
19 binds to the cavity formed by the transmembrane helices 2, 3, 6, and 7 of CCR5 receptor,
which is different with the binding site of TAK-799.82 Radioligand binding competition
assays demonstrated that 19 blocks the binding of gp120 to CCR5, resulting in the
prevention of membrane fusion events necessary for viral entry. Compound 19 inhibits some
downstream CCR5 signaling events following its inhibition of several natural chemokine
ligands such as MIP-1α, MIP-1β, and RANTES. However, it does not trigger release of
intracellular calcium or CCR5 internalization, indicating that it is devoid of CCR5 agonist
activity. Thus, 19 is a functional antagonist of CCR5.78 In clinical trials, it was administered
orally with twice-daily dosing.83 In August 2007, 19 was approved by the US FDA as a
CCR5 antagonist HIV entry inhibitor under the brand name Selzentry.
Vicriviroc (SCH-D, SCH-417,690, Schering-Plough) (23) (Fig. 6), a piperzine-based CCR5
antagonist, is also currently in Phase III clinical study. It is a second-generation compound
with improved anti-HIV activity and pharmacokinetic profile compared with the first-
generation ancriviroc (SCH-C, SCH-351,125, Schering-Plough) (24) (Fig. 6), a piperidino-
piperidine derivative.84,85 Both compounds are orally bioavailable and interact within the
cavity formed by CCR5 transmembrane regions, resulting in inhibition of HIV gp120
binding.86 Compound 24 was discovered first by modification of a high throughput
screening lead. However, later study revealed that high doses of 24 led to CNS side effects
and prolongation of the corrected QT cardiac interval (QTc interval: the time between
depolarization and repolarization of the heart muscle adjusted for heart rate; the longer the
QTc interval, the slower the heart rate).85 The clinical studies of 24 were then discontinued.
Within the piperazino-piperidine series, replacing the N-oxide of 25 by 4,6-
dimethylpyrimidine carboxamide as in 26 (Fig. 6) resulted in better CV profiles.84 Further
optimization of 26 led to the discovery of vicriviroc (23), which has potent, broad-spectrum
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antiviral activity against diverse HIV-1 subtypes and synergistic anti-HIV activity in
combinational use with drugs from other classes. Another promising candidate in the
piperazino-piperidine family is AD101 (SCH-350,581) (27) (Fig. 6), which also shows
potent anti-HIV-1 activity by blocking gp120/CD4 complex and CCR5 interaction. AD101
is currently in preclinical study.87
INCB9471 (Incyte Corporation) (28) (Fig. 7) is another promising candidate in Phase II
clinical trials. It also belongs to the piperazino-piperidine family. The similar structures of
INCB9471 and vicriviroc suggest that they might share the same mechanism of action.
INCB9471 is an orally bioavailable CCR5 antagonist with very potent antiviral activity
against a wide range of HIV-1 strains, including drug resistant isolates.88
Aplaviroc (GW873140, formerly ONO4128, AK602, GlaxoSmithKline) (29) (Fig. 7) failed
in Phase II clinical trials in October 2005, due to unexpected serious hepatotoxicity. It
belongs to the spirodiketopiperazine family and exhibits potent antiviral activity with IC50
values around 0.1–0.6 nM.89 Aplaviroc exerts its antiviral function by interacting with
CCR5 ECL2 rather than binding to the CCR5 transmembrane cavity, which is distinct from
other CCR5 antagonists.89,90
Other classes of compounds have also been reported to be CCR5 antagonists.
GlaxoSmithKline filed a patent (WO2004054974) describing some newly discovered anti-
HIV-1 CCR5 antagonists. Among these compounds, GSK 163929 (30) (Fig. 8) showed
nanomolar level inhibition activity towards HIV replication and successfully completed
preclinical studies.91 NSC651016 (31) (Fig. 8) inhibits chemokine binding of CCR5,
CXCR4, CCR1, and CCR3, but does not interact with CXCR2 or CCR2b. It inhibits a wide
range of HIV-1 variants and HIV-2 isolates, and could be developed as a topical
microbicide.92 Shikonin (32) (Fig. 8), a major component of purple gromwell (zicao, dried
root of Lithospermum erythrorhizon) is a CCR5 chemokine antagonist with sub-micromolar
level antiviral activity.93 Merck reported the discovery of several compounds (33–37) (Fig.
9) with potent CCR5 binding affinity. However, the anti-HIV activities of these compounds
are only moderate.94–97
2. CXCR4 Inhibitors—Although the deletion of CCR5 has little impact on an individual’s
health, CXCR4 is involved in a number of physiological processes. In a mice knockout
study, knocking out either CXCR4 or its only known natural ligand SDF-1 (stromal cell-
derived factor) resulted in abnormal cerebral development and was embryonically
lethal.98,99 Whether CXCR4/SDF-1 is vital only in embryonic development needs to be
further determined. Deletion of SDF-1 also caused defects in B-cell lymphopoiesis and bone
marrow myelopoiesis in mice.100 These findings make CXCR4 antagonists less feasible.
However, although R5 variants are dominant in initial HIV transmission, a switch in co-
receptor use occurs after transmission, and the virus gains ability to use both R5 and X4
during AIDS progression.62 Therefore, CXCR4 antagonists are still necessary. The ideal
CXCR4 antagonist should block HIV entry without affecting CXCR4 down-stream
signaling pathways or causing CXCR4 internalization.
The initial strategy for developing CXCR4 antagonists also focused on mimics of the
CXCR4 natural ligand SDF-1. T-22 is a synthetic 18 amino-acid peptide with highly polar
cationic character.101 Its downsized analogs T134 and T-140 contain fourteen amino-acid
residues.102,103 Both compounds inhibit replication of X4 isolates by specifically binding to
the CXCR4 co-receptor. Further SAR study concluded that four amino-acid residues, Arg2,
NaI3 [L-3-(2-naphthyl)alanine3], Tyr5, and Arg14, are essential for T-140 antiviral potency
(IC50 ~ 60 nM)104 which led to the identification of FC131 [cyclo(-L-NaI1-L-Gly2-D-Tyr3-
L-Arg4-L-Arg5-)] with antiviral IC50 around 38 nM.105
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ALX40-4C (N-α-acetyl-nona-D-arginine amide) is the first co-receptor inhibitor to be tested
in humans prior to the elucidation of its mechanism of action as a CXCR4 antagonist.106
Unfortunately, development of this compound was stopped due to negligible reduction of
viral load in clinical studies.
Norvatis Ltd. reported the discovery of a nine-residue hybrid peptoid/peptide oligomer,
CGP64222, which specifically blocks the CXCR4 co-receptor binding.107 It shows anti-HIV
activity at a nanomolar concentration.108 Mechanism of action study further revealed that
CGP64222 also inhibits Tat/TAR RNA interaction as a second mechanism of action to
inhibit HIV replication. (Recruitment of Tat protein to the transcription machinery after its
binding to the RNA response element TAR is one of the first steps in HIV gene expression.)
In addition to large molecule polypeptides, several small molecule CXCR4 antagonists are
also under development. AMD3100 (AnorMED, Inc., now Genzyme Corporation) (38) (Fig.
10) is a low molecular weight bicyclam analog with potent anti-X4 HIV variant activity
(IC50 ~ 1.4 nM).109 Its development was terminated when abnormal cardiac activity was
observed in Phase II clinical studies. The second generation cyclam analog AMD3465 (39)
(Fig. 10) has only one cyclam unit; the other is replaced by N-pyridinylmethylene.110
However, although the antiviral activity of 39 is slightly better than that of 38, it still lacks
oral bioavailability. The mechanism of action of cyclam analogs is related to the multiple
positive charges associated with the basic nitrogen atoms,111 which interact with negatively
charged acidic residues in CXCR4. Studies showed that residues D171, D262, and E288 are
important in CXCR4 binding by 38.111 The third generation AMD070 (AMD11070) (40)
(Fig. 10) is structurally different from the prior analogs and is also orally bioavailable.112 It
is highly specific for the CXCR4 receptor. Compounds 38 and 40 have similar binding
sites111 and exhibits similar antiviral activity against a broad range of X4 and R5X4 isolates,
but are not active against R5 strains. Compound 40 is currently in Phase II clinical trials.
KRH-1636 (Kureha Chemical Industries) (41) is an arginine-based CXCR4 antagonist with
good anti-HIV-1 activity (IC50 ~ 42 nM).113 It was obtained from optimization of a high
throughput screening lead. It can be absorbed after intraduodenal administration to rats,
suggesting that it may be orally bioavailable.113 Further modification led to the discovery of
KRH-2731 · 5HCl (structure has not been released), which is a 41-analog with improved
antiviral potency (IC50 = 1.0 nM) against X4 and R5X4 HIV isolates.114 KRH-2731 · 5HCl
is orally bioavailable. Mechanism of action study revealed that it binds to ECL2 and ECL3
(second and third extracellular loops) of the CXCR4 receptor.65
Qian et al. Page 8














As previously mentioned, the binding of CD4/gp120 complex with a chemokine co-receptor
leads to a conformational rearrangement in gp120 that enables gp41 to reorient parallel to
viral and cellular membranes and expose a highly hydrophobic fusion-peptide (FP) region of
trimeric gp41, which will later insert into the cell membrane. FP is located at the N-terminus
of gp41, adjacent to two heptad repeats (HRs). During the fusion process, HR1 and HR2
form a thermostable, six-helix bundle structure.23,26 The change in free energy associated
with this critical step provides the force needed for formation of the fusion pore, through
which the viral capsid is released into the target cell.26
1. Large Molecule Fusion Inhibitors—As early as the 1990s, researchers realized that
synthetic peptides based on the HR1 and HR2 sequences of gp41 have anti-HIV
properties.115,116 The mechanism of action of this oligopeptide class is believed to be
competitive binding of the synthetic peptides with the corresponding HR regions, which is
also called the “dominant-negative inhibition model”.17
Until now, fusion inhibitors have been the most successful class of HIV entry inhibitors.
Enfuvirtide (T20, Fuzeon, Trimeris/Roche) (42) was approved for use in combination with
other ARTs in treatment-experienced patients in March 2003 by the US FDA.117,118 It is a
36-amino acid synthetic peptide that mimics the HR2 region (residues 127–162 in C-
terminal) of gp41.118 By competitively binding to the HR1 region of gp41, 42 prevents the
formation of the six-helix bundle structure that is critical as the energy source for the fusion
process.119 Compound 42 shows good antiviral potency and long-term safety in clinical use.
A synergistic effect has also been observed in its combinational use with other ARTs.
However, it is administered by subcutaneous injection of 90 mg twice daily, which is highly
inconvenient. Moreover, inhibitor-naive primary HIV-1 isolates exhibited wide ranging
susceptibilities to 42, and the compound has a relatively low genetic barrier for
resistance.120 Thus, enfuvirtide is considered only a second-line antiretroviral agent.
The second-generation fusion inhibitor tifuvirtide (T-1249) shows 10-fold more potent
antiviral activity compared with 42.121 It preserves antiviral efficacy to 42-resistant HIV-1
isolates as well as HIV-2 and SIV variants,121 and is a 39-amino acid peptide mimicking a
different region of HR2.122 However, its clinical development was halted due to formulation
challenges.123
TRI-999 and TRI-1144 (Trimeris)124 are additional oligopeptide fusion inhibitors, which
show better pharmacokinetic profiles. Using rational design, researchers in Trimeris further
designed a series of oligomeric HR2 peptides with increased helical structure that self-
associate into stable oligomeric structures, resulting in exceptionally high HR1/HR2 bundle
stability.125 The engineered peptides (e.g., T-2635, T-267221, T-267227) are found to be as
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much as 3,600-fold more active than 42 and T-1249 against HR2-resistant viruses, and are
shown to have 100-fold improved pharmacokinetics in cynomolgus monkeys. More
importantly, viruses appear to require more mutations to decrease sensitivity to the
engineered peptides, and the impact of these mutations on activity is significantly less than
that observed for 42.125 Taken together, these newly engineered peptides are attractive for
further clinical development.
5-Helix is a chimeric gp41 containing three N- and two C-terminal helices connected by a
linker, which showed nanomolar activity against diverse HIV-1 isolates by targeting the
HR2 region of gp41.126
2. Small Molecule Fusion Inhibitors—Recent Progress With Triterpene
Derivatives as HIV Entry Inhibitors—Until now, most reported fusion inhibitors have
been large polypeptides, which lack oral bioavailability and are relatively costly. The azo
dye ADS-J1 (43) was originally defined as a fusion inhibitor;127 however, recent study
discovered that it acts before the gp41-dependent fusion step.128 Small molecules that can be
easily purified during manufacture and are more likely to be orally administrated hold better
potential to be developed into clinical drugs.
a. Discovery of RPR103611 and IC9564: Certain triterpene derivatives represent
promising small molecule fusion inhibitors (exact binding site is currently unknown, but it
has been demonstrated that this compound class functions at a post-binding, envelope-
dependent step involved in fusion of the virus to the cell membrane, as discussed below).
Betulinic acid (BA, 3β-hydroxy-lup-20(29)-en-28-oic acid, 44) and platanic acid (45), both
of which are pentacyclic triterpenes extracted from Syzigium claviflorum, were first
reported in 1994 to suppress HIV-1IIIB replication in vitro, with IC50 values of 1.4 and 6.5
μM, respectively.129 Because of its promising anti-HIV activity and ready availability from
various natural sources, including white birch trees, BA was selected as a lead in an anti-
HIV drug discovery program.
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C-28 ω-aminoalkanoic acid derivatives of BA were then synthesized and evaluated for
antiviral activity by Soler et al.130 Initially, the chain length between the C-28 amide bond
moiety and the terminal carboxylic acid group (46a–l, m = 1–12) (Fig. 11) was explored,
and incremental chain lengthening significantly influenced the anti-HIV-1 potency of the
derivatives. Compounds with amide side chains between amino-octanoic acid and amino-
dodecanoic acid (46g–k, m = 7–11) showed increased antiviral potency, with amino-
undecanoic acid (46j, m = 10) being optimal. Condensation of these C-28 ω-aminoalkanoic
acid derivatives with a second aminoalkanoic acid produced compounds with two amide
moieties at different positions of the C-28 side chain. It was then discovered that small
peptide amide derivatives of the parent octanoic acid analog 46g were more potent than both
the parent compound and 46j. The presence of a small lipophilic space between the two
amide moieties increased the anti-HIV-1 activity of 46g by around 10-fold, and substituents
on this second aminoalkanoic acid moiety also modulated the antiviral potency. This effort
led to the discovery of RPR103611 (47) (Fig. 11), a statine derivative, which inhibits the
infectivity of several HIV-1 strains in a 10 nM concentration range.130,131
Research in the authors’ laboratories on BA derivatives as HIV entry inhibitors focused on
the modifications in the isopropylene and C-28 side chains. The study showed that IC9564
(48) (Fig. 11), a stereoisomer of RPR103611, exhibits equally potent anti-HIV-1 activity.132
This same study also revealed that dihydro-IC9564 (49) (Fig. 11), with a saturated isopropyl
rather than isopropenyl group, and 50, a L-leucine derivative of (betulinylamino)-undecyclic
acid (Fig. 11) also were equipotent against HIV-1 virus compared with RPR103611 and
IC9564.132 Compound 50 is synthesized more easily than RPR103611 and IC9564.
Other triterpene skeletons, including glycyrrhetinic acid (GLA, 51), moronic acid (MA, 52),
oleanolic acid (OA, 53), and ursolic acid (UA, 54) as well as their derivatives modified at a
position corresponding to C-28 of BA, were also synthesized and evaluated.133 However,
none of these analogs were better than RPR103611 and IC9564, indicating that the BA
triterpenoid skeleton itself, in addition to the C-28 side chain moiety, is also a
pharmacophore for antiviral potency.
b. Mechanism of action study of RPR103611 and IC9564: RPR103611 does not inhibit
RT, integrase, or protease. A time-of-addition assay indicated that postponing the addition
time of RPR103611 for 2 h cancelled its inhibitory potency on HIV-1 replication, suggesting
that this compound functions at an early stage of the virus life cycle.131 A virus binding
assay using recombinant soluble CD4 ruled out the possibilities that attachment of virus to
target cells or CD4-gp120 binding were inhibited. RPR103611 does blockage syncytium
formation, which indicates that it functions at a post-binding step necessary for virus-
membrane fusion. Thus, this compound is the first nonpeptidic small molecule found to act
as a fusion inhibitor.131
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A sequence analysis of RPR103611-resistant mutants indicated that a single amino acid
change, I84S, in the HIV-1 gp41 region is sufficient to confer drug resistance.134 The I84
residue is highly conserved and is only rarely replaced by another hydrophobic residue (e.g.,
phenylalanine). However, I84 is also found in gp41 of some naturally RPR103611-resistant
HIV-1 strains, such as NDK or ELI.134 Thus, although the drug-resistant mutants occur on
gp41, it would be imprudent to conclude that gp41 is the direct target for RPR103611. It is
possible that the mutation of I84 to a polar amino acid may alter the gp41 conformation so
that the stability of the gp120-gp41 complex is affected.134 The mutation could also modify
access of a compound to a target on gp120. Indeed, a later study from the same group
reported that the antiviral efficacy of RPR103611 depends on both the sequence of the gp41
loop region (I84, L91) and the stability of the gp120-gp41 complex.135 Virus with a
decreased affinity between gp120 and gp41 is more susceptible to RPR103611.135
A mechanism of action study on IC9564 by Chen et al. revealed that mutations in gp120 are
responsible for resistance to the compound.136 No mutations on gp41 were found to
significantly affect the antiviral activity of the compound.136 However, this discovery does
not rule out the possibility that IC9564 and RPR103611 share the same mechanism of
action, since IC9564-resistant viral strains carry mutations of G237R and R252K, which
locate in the inner domain of gp120 core. The inner domain of gp120 is believed to interact
with gp41, indicating that these mutations on gp120 may also affect the affinity between
gp120 and gp41.136 In this particular study, no mutations were found in the regions of gp120
that are well defined for CD4 binding or chemokine co-receptor binding. In continuing
studies, a conformational change in gp120 induced by IC9564 was observed by using
conformational monoclonal antibody.137,138 It was discovered that IC9564 induces a
nonproductive gp120 conformation that is not able to trigger a conformational
rearrangement in gp41 for membrane fusion.138 This discovery supports the previous
speculation that triterpenes in this class function as nonpeptidic small molecule fusion
inhibitors.
In their most recent publication, Dr. Chen’s group reported that IC9564 can increase the
antiviral activity of TAK-779 by more than 100-fold.139 Mutations near the tip of the V3
loop were found among IC9564 escaping viruses. Moreover, IC9564 can compete with the
binding of V3 loop monoclonal antibodies and with the binding of CD4-gp120 complex to
chemokine receptors.139 These results suggested that IC9564 may also function by targeting
the V3 loop of gp120, a domain involved in chemokine receptor binding.139,140 The exact
binding target of triterpene derivatives is still under investigation.
c. Current status of triterpene derivatives as potent HIV-1 inhibitors: Interestingly, the
anti-HIV-1 targets of triterpene analogs can vary depending on the side chain modification
positions. C-28 modified BA analogs are potent HIV entry inhibitors, while C-3 modified
BA derivatives function by blocking virus maturation.16 Bevirimat (DSB, PA-457, Panacos
Pharmaceuticals) (55), which is a C-3 substituted dimethylsuccinyl BA analog, represents
the first HIV-1 maturation inhibitor. It is currently in Phase IIb clinical trials and shows
good oral bioavailability, safety and pharmacokinetic profiles.141–145 It is encouraging that
triterpene analogs can be safely and efficiently used in humans.
Recent progress in this research area has included the development of bi-functional BA
analogs, which contain both the C-3 and C-28 side chains, such as A12-2 (56), with IC50
value of 2.6 nM.146 This category of compounds preserves the anti-HIV-1 entry and anti-
HIV-1 maturation activities of the parent compounds, and shows a synergistic effect on
antiviral potency.
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With increasing knowledge of the HIV entry process, various targets involved in different
stages of viral entry have emerged. Inhibitors of these novel targets hold great potential to
supplement current HAART, especially to treat individuals harboring multidrug-resistant
virus. The success of enfuvirtide and maraviroc validates the clinical application of viral
entry inhibitors as a new class of antiretroviral drugs. Many more HIV entry inhibitors,
including attachment inhibitors, co-receptor binding inhibitors and fusion inhibitors, are
currently in clinical trials, and some have already advanced to Phase III clinical studies.
However, along with great success in the development of HIV entry inhibitors, some
problems also arise. It is well known that the envelop glycoprotein is among the most
variable HIV proteins with diverse genotypes. Thus, the susceptibility of treatment-naive
viral strains to different entry inhibitors targeting viral envelop glycoprotein may vary
significantly. In addition, co-receptor binding inhibitors are phenotype specific, including
CCR5 antagonists and CXCR4 antagonists. Thus, HIV patients must be analyzed for which
viral isolates (R5, X4, or R5/X4) they harbor for appropriate selection of treatment with
CCR5 or CXCR4 antagonist. Moreover, because CCR5 and CXCR4 co-receptors are
actually a host cellular target rather than a viral enzyme or glycoprotein target, the long-term
efficacy and safety of drug use must also be closely monitored. The recent FDA approval of
maraviroc as the first CCR5 antagonist HIV entry inhibitor, however, suggests that this class
of entry inhibitors may be safely used in HIV-infected individuals. This approval, together
with the approval of the first fusion inhibitor enfuvirtide, further confirms that HIV entry
inhibitors represent significant complements to AIDS therapy. With the emergence of HIV
virus resistant to different current ARTs, the development of new drugs with novel targets is
still the focus of much research.
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APPENDIX
Pharmaceutical Companies
Aronex Pharmaceuticals, 8707 Technology Forest Place, The Woodlands, TX 77381-1191
Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US)
Cellegy Pharmaceuticals Inc., 2085 B Quaker Pointe Rd., Quakertown PA 18951
Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142
GlaxoSmithKline US Headquarters, 1500 Spring Garden St, Philadelphia, PA 19130
Incyte Corporation, Experimental Station, Route 141 & Henry Clay Road, Building E336,
Wilmington, DE 19880
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Indevus Pharmaceuticals, Inc. - NJ, 7 Clarke Drive, Cranbury, NJ 08512
Kureha Chemical Industries, 3-3-2, Nihonbashi-Hamacho, Chuo-ku, Tokyo 103-855
Novartis, Ltd., Pharmaceuticals, Pharma Research, CH-4002 Basle, Switzerland
Panacos Pharmaceuticals, Gaithersburg, Maryland Research & Development Facility, 209
Perry Parkway, Suite 7, Gaithersburg, Maryland 20877
Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Progenics Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591
Schering-Plough Corporation, World Headquarters, 2000 Galloping Hill Road, Kenilworth,
NJ 07033-0530
Tanox Inc., 10555 Stella Link, Houston, TX 77025
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Structures of some selected sulfated compounds as HIV nonspecific attachment inhibitors.
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Selected structures of CD4-gp120 binding inhibitors.
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Structures of modified chemokine derivatives as HIV inhibitors.
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Structures of TAK analogs.
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Lead optimization and identification of Maraviroc.
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Structures of Vicriviroc and Ancriviroc analogs.
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Structures of INCB9471and Aplaviroc.
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Selected structures of promising CCR5 antagonists as anti-HIV agents.
Qian et al. Page 32














Merck analogs showing potent CCR5 binding affinity.
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Structures of AMD analogs.
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C-28 modified BA as HIV entry inhibitors.
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